Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $1.29 in the prior trading day, Xilio Therapeutics Inc (NASDAQ: XLO) closed at $1.04, down -19.38%. In other words, the price has decreased by -$19.38 from its previous closing price. On the day, 1.22 million shares were traded. XLO stock price reached its highest trading level at $1.29 during the session, while it also had its lowest trading level at $0.9.
Ratios:
Our goal is to gain a better understanding of XLO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.02 and its Current Ratio is at 2.02. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Chardan Capital Markets on December 21, 2022, initiated with a Buy rating and assigned the stock a target price of $7.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $36.
On November 16, 2021, Raymond James started tracking the stock assigning a Outperform rating and target price of $31.Raymond James initiated its Outperform rating on November 16, 2021, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 02 ’24 when GILEAD SCIENCES, INC. bought 485,250 shares for $0.76 per share. The transaction valued at 368,790 led to the insider holds 7,345,473 shares of the business.
Atlas Venture Fund XI, L.P. sold 733 shares of XLO for $469 on Feb 08 ’24. The 10% Owner now owns 2,019,563 shares after completing the transaction at $0.64 per share. On Feb 08 ’24, another insider, Atlas Venture Fund XI, L.P., who serves as the 10% Owner of the company, sold 267 shares for $0.64 each. As a result, the insider received 171 and left with 734,546 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XLO now has a Market Capitalization of 45710600 and an Enterprise Value of -9561287. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.37 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at -4.057 whereas that against EBITDA is 0.147.
Stock Price History:
Over the past 52 weeks, XLO has reached a high of $2.14, while it has fallen to a 52-week low of $0.49. The 50-Day Moving Average of the stock is 18.52%, while the 200-Day Moving Average is calculated to be 13.41%.
Shares Statistics:
The stock has traded on average 231.35K shares per day over the past 3-months and 644580 shares per day over the last 10 days, according to various share statistics. A total of 27.61M shares are outstanding, with a floating share count of 21.31M. Insiders hold about 51.52% of the company’s shares, while institutions hold 14.59% stake in the company. Shares short for XLO as of 1728950400 were 104746 with a Short Ratio of 0.45, compared to 1726185600 on 14750. Therefore, it implies a Short% of Shares Outstanding of 104746 and a Short% of Float of 0.29.
Earnings Estimates
Xilio Therapeutics Inc (XLO) is presently subject to a detailed evaluation by 3.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.17 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.0 and -$1.54 for the fiscal current year, implying an average EPS of -$1.26. EPS for the following year is -$0.58, with 3.0 analysts recommending between $0.01 and -$0.89.
